-

bioMérieux: Notice of Information Related to Preparatory Documents for the Ordinary and Extraordinary Shareholders’ Meeting of May 20, 2021

LYON, France--(BUSINESS WIRE)--Regulatory News:

An Ordinary and Extraordinary Shareholders’ Meeting of bioMérieux (Paris:BIM) is called at 2:00 p.m. on May 20, 2021 at 376 Chemin de l'Orme, Marcy l'Étoile (69280), France.

The practical information about voting, the agenda and proposed resolutions are outlined in the preliminary notice published in the French Bulletin of Compulsory Legal Announcements (Bulletin des Annonces Légales Obligatoires) on April 9th, 2021 (number 43), and on Company’s website at www.biomerieux.com (Investors > Shareholders Area > General Shareholders Meetings).

In view of the ongoing health crisis, the Company may have to modify the conditions for participating in this Annual General Meeting. Consequently, shareholders are encouraged to regularly consult the Company’s website at www.biomerieux.com (Investors > Shareholder Area > General Shareholders’ Meeting), which may be updated to specify the definitive conditions for participating in the Annual General Meeting, depending on health and/or legal requirements.

Shareholders may obtain the documents referred to in Articles R. 225-81 and R. 225-83 of the French Commercial Code (Code de Commerce) by sending a simple request to à BNP Paribas Securities Services, CTO, Service Assemblées, Grands Moulins de Pantin, 9, rue du Débarcadère, 93761 Pantin Cedex or to the email address investor.relations@biomerieux.com.

The documents and information referred to in Article R. 225-73-1 of the French Commercial Code (Code de Commerce) will be made available on the Company's website at www.biomerieux.com (Investors > Shareholders Area > General Shareholders Meetings) no later than from the twenty-first day before the Annual General Meeting, i.e., April 29, 2021.

Financial information and official communications on www.biomerieux.com/Investors

Contacts

bioMérieux

bioMérieux

BOURSE:BIM

Release Versions

Contacts

bioMérieux

More News From bioMérieux

bioMérieux Announces the CE Marking of TB IGRA® Test on VIDAS®

MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: Today marks World Tuberculosis (TB) Day and bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection. Tuberculosis continues to be a major global health problem. With 10 million new active cases and 1.4 million related deaths worldwide in 20191, TB remains an important cau...

bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization

MARCY L’ÉTOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the c...

bioMérieux – 2020 Financial Results

MARCY L’ETOILE, France--(BUSINESS WIRE)--Regulatory News: bioMérieux (Paris:BIM): Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In the unprecedented crisis the world has been facing for a year, bioMérieux has been strongly mobilized and has proven once again how relevant its solutions are. Our positioning as an In Vitro Diagnostics specialist and our development of solutions adapted to the detection of COVID-19 has allowed us to deliver a remarkable commercial and financial pe...
Back to Newsroom